Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With METamp After Osimertinib First-Line Treatment

JCO Precis Oncol. 2022 Oct:6:e2200367. doi: 10.1200/PO.22.00367.

Affiliations

¹ Medical Oncology Department, A.C. Camargo Cancer Center, R. Professor Antonio Prudente, São Paulo, Brazil.
² Department of Pathology, R. Professor Antonio Prudente, São Paulo, Brazil.
³ Genomics and Molecular Biology Group, International Research Center/CIPE, A.C. Camargo Cancer Center, São Paulo, Brazil.
⁴ National Institute of Science and Technology in Oncogenomics (INCITO), São Paulo, Brazil.

PMID: 36201715
DOI: 10.1200/PO.22.00367

No abstract available

MeSH terms

Acrylamides
Adenocarcinoma of Lung* / drug therapy
Aniline Compounds
ErbB Receptors / genetics
Humans
Indoles
Lung Neoplasms* / drug therapy
Pyrazines
Pyrimidines
Triazines

Substances

Acrylamides
Aniline Compounds
Indoles
Pyrazines
Pyrimidines
Triazines
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
osimertinib
EGFR protein, human
ErbB Receptors